. Author manuscript; available in PMC: 2009 Feb 1.

Published in final edited form as: J Mol Cell Cardiol. 2007 Nov 24;44(2):315–322. doi: 10.1016/j.yjmcc.2007.11.006

TABLE I.

Isolated retrograde perfused heart function (midpoint) and energy potential at baseline workloads (Protocol 1) and during an adrenergic challenge (Isoproterenol; Protocol 2).

	SHAM		HEART FAILURE
	Baseline	Isoproterenol	Baseline	Isoproternol
Heart Rate, bpm	282 ± 14	336 ± 9 ^†	259 ± 26	326 ± 13 ^¶
LVDP, mm Hg	116 ± 13	186 ± 18 ^†	86 ± 14 ^*	131 ± 8 ^§^¶
RPP, mmHg^*beats/min	33840 ± 4859	63801 ± 3834 ^†	21665 ± 3530 ^*	43010 ± 3051 ^§^¶
(+)dp/dt, mmHg/sec	3151 ± 498	5306 ± 215 ^†	2301 ± 390 ^*	3122 ± 219 ^§^¶
(−)dp/dt, mmHg/sec	2971 ± 433	5452 ± 344 ^†	2284 ± 298 ^*	3777 ± 233 ^§^¶
PCr/ATP (endpoint)	2.11 ± 0.05	1.94 ± 0.09	1.43 ± 0.10 ^*	1.34 ± 0.08 ^§

Mean ± S.E.; Significant difference at p<0.05 for

Isoproterenol

Sham baseline vs HF baseline

^†

Sham baseline vs Sham

^§

Sham Isoproterenol vs HF

^¶

HF baseline vs HF Isoproterenol